Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage Plasmodium falciparum parasites
about
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)Leaving the lysosome behind: novel developments in autophagy inhibitionSurfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI InhibitorsOpen Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondBilayer Effects of Antimalarial CompoundsBiological characterization of chemically diverse compounds targeting the Plasmodium falciparum coenzyme A synthesis pathwayState-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.Virtual Screening and Experimental Validation Identify Novel Inhibitors of the Plasmodium falciparum Atg8-Atg3 Protein-Protein Interaction.Metabolomics-Based Screening of the Malaria Box Reveals both Novel and Established Mechanisms of Action.New insight-guided approaches to detect, cure, prevent and eliminate malaria.Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.The Candidate Antimalarial Drug MMV665909 Causes Oxygen-Dependent mRNA Mistranslation and Synergizes with Quinoline-Derived Antimalarials.ATG8 Is Essential Specifically for an Autophagy-Independent Function in Apicoplast Biogenesis in Blood-Stage Malaria Parasites.Characterization of Plasmodium Atg3-Atg8 interaction inhibitors identifies novel alternative mechanisms of action in Toxoplasma gondii.Using Yeast Synthetic Lethality To Inform Drug Combination for Malaria.Novel Antifungal Compounds Discovered in Medicines for Malaria Venture's Malaria Box.
P2860
Q22676705-0F86A7BF-B526-46DA-B413-63D1D239B3BCQ26774549-442CB722-EFB0-4BEF-89CA-F52D32811E16Q26823990-DEC3D988-3557-4A87-8AE5-111EE51E537DQ27826351-0C0B297E-1A48-40D6-9D48-DC060F4595ADQ28550778-B88E1630-3C66-40B6-81E0-498C8AF803B2Q28821118-378620AB-19DE-4693-A18C-652050C69FD9Q35738960-E2B132E5-EA78-4A90-997C-C2DFB86742CDQ35889533-5CD20579-B134-4F13-BB9D-8390C83AE92BQ36116227-70A6FD20-3C2A-4E89-A570-30A8BEF3688AQ38260909-5F90DFF7-CE33-493D-8D15-6725AFCC4580Q38695331-AD7E33C7-86E9-4956-B154-0AD7A4C9C03FQ38708103-96B4556B-2111-4313-BD4E-CFF77A6EA335Q47139873-749DAD75-9978-4FCD-BE4A-09D703E2811BQ47381598-31D76174-7E25-4AB0-BD6E-E70480D21CAEQ47557866-10A01610-4A5A-45BB-A2E9-993E82CCCCC3Q52725067-5E2572D8-A412-4AB1-877E-9C028BD1BF4F
P2860
Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage Plasmodium falciparum parasites
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Identification of an Atg8-Atg3 ...... lasmodium falciparum parasites
@ast
Identification of an Atg8-Atg3 ...... lasmodium falciparum parasites
@en
Identification of an Atg8-Atg3 ...... lasmodium falciparum parasites
@nl
type
label
Identification of an Atg8-Atg3 ...... lasmodium falciparum parasites
@ast
Identification of an Atg8-Atg3 ...... lasmodium falciparum parasites
@en
Identification of an Atg8-Atg3 ...... lasmodium falciparum parasites
@nl
prefLabel
Identification of an Atg8-Atg3 ...... lasmodium falciparum parasites
@ast
Identification of an Atg8-Atg3 ...... lasmodium falciparum parasites
@en
Identification of an Atg8-Atg3 ...... lasmodium falciparum parasites
@nl
P2093
P2860
P921
P3181
P356
P1476
Identification of an Atg8-Atg3 ...... lasmodium falciparum parasites
@en
P2093
Adelaide U P Hain
Alexia S Miller
Caren Freel Meyers
David J Sullivan
Jelena Levitskaya
Natalie G Sanders
P2860
P304
P3181
P356
10.1021/JM401675A
P407
P577
2014-05-19T00:00:00Z